Australian patent granted for selected compounds for chronic wound therapy
INJECTHEAL Project kick-off meeting
Full title of the project: “Multifunctional Self-Healing Injectable Hydrogel for Chronic Wound Healing and Tissue Regeneration”
Akribes is part of the INJECTHEAL consortium, which consists of 13 partners from 8 European countries (Italy, Austria, Germany, Ireland, Spain, Switzerland, and the UK), with the aim of contributing to the advancement of knowledge and applications in the field of chronic wound healing.
At the heart of the project is the development of a 4D injectable self-healing hydrogel, designed for the targeted release of medications into complex wounds, contributing to the reduction of inflammation and infection and supporting tissue regeneration. The hydrogel will be developed using sustainable materials, with the goal of providing an advanced therapeutic option, particularly for deep cavity wounds.
INJECTHEAL is funded by the European Union through the Horizon Europe research and innovation programme (project duration: three years).
Please follow the project on LinkedIn @INJECTHEAL Project and Instagram @injectheal.project.
Chinese patent granted for selected compounds for chronic wound therapy
Confirmation of Phase 2-readiness of AKR101-documentation for a clinical study in chronic wound patients.
The Federal Institute for Drugs and Medical Devices in Germany, BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte), confirms in a scientific advice meeting that the documentation of AKR101 is ready for a Phase 2 clinical study in chronic wound patients.
Patent for selected compounds for chronic wound therapy granted in Singapore
Japanese patent granted for selected compounds for chronic wound therapy
FORCE REPAIR update with an animated illustration of the EU project and a new online interview with Gabriela Cabral from the Akribes team
The FORCE REPAIR Team has produced an animated video to explain how #FORCEREPAIR strives to advance chronic wound management by developing a smart, multi-functional, and cost-effective 3D-printed wound dressing.
See also the new interview online: “Meet Gabriela Cabral” from the Akribes team
https://www.forcerepair-wounds.eu/interviews#gabriela-cabral
EU patent granted for selected compounds for chronic wound therapy
US patent granted for selected compounds for chronic wound therapy
US patent granted for theranostic assay platform